Thermogenesis für das Langfristdepot - 500 Beiträge pro Seite
eröffnet am 21.02.02 17:31:23 von
neuester Beitrag 28.02.02 19:48:52 von
neuester Beitrag 28.02.02 19:48:52 von
Beiträge: 24
ID: 554.855
ID: 554.855
Aufrufe heute: 0
Gesamt: 518
Gesamt: 518
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 12 Minuten | 7253 | |
| vor 11 Minuten | 6499 | |
| vor 1 Stunde | 4924 | |
| vor 55 Minuten | 4738 | |
| vor 7 Minuten | 4336 | |
| heute 19:35 | 2745 | |
| vor 1 Stunde | 2500 | |
| vor 25 Minuten | 2207 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.179,00 | +1,33 | 210 | |||
| 2. | 2. | 147,34 | +10,75 | 92 | |||
| 3. | 19. | 0,1945 | +5,71 | 91 | |||
| 4. | 3. | 2.322,82 | -0,19 | 63 | |||
| 5. | 43. | 0,0262 | +63,75 | 49 | |||
| 6. | 9. | 43,75 | -3,42 | 48 | |||
| 7. | 17. | 4,7480 | +3,15 | 40 | |||
| 8. | 5. | 718,80 | +7,09 | 36 |
Feedback
Guten Tag, achtet doch mal auf Thermogenesis, Kürzel KOOL an der Nasdaq, WKN 883496 bei uns. Gute News in den letzten Wochen, dazu sehr viel Phantasie. Scheint so, als wollte der Kurs nach oben. Mal selbst nachsehen. Grüsse
grössere Nachfrage als gewöhnlich heute, könnten also weitere positive News anstehen.
heute bereits 6% im Plus. Die Aktie wurde vor ca. 2 Jahren mal von einem "Biotec-Spezialisten" empfohlen, wie auch Aastrom und Peregrine. Daraufhin ging es uf über 5E, und genau dort wird es auch mindestens wieder hingehen. Natürlich nicht heute, aber es ist ja auch langfristig gedacht.
Scheinen ja wirklich nur kurzfristig Orientierte hier im Board zu sein. Pech gehabt.
hallo Rudi D., worin besteht denn die Phantasie? Stammzellen? Bin langfristig orientiert, habe mir KOOL beim Hype vor 2 Jahren ins Depot gelegt, aber immer geahnt,dass daraus mal etwas wird.
Trading Spotlight
Schöner Tag gestern, da sollte doch heute eigentlich eine dicke Meldung kommen. Oder, die Aktie wird langsam etwas mehr beachtet. Wir werden sehen. Grüsse
die interessantere Frage ist doch die, wie sich ein
OTC Markt Interessierter den Namen eines Mannes zulegt,
der mit solchen Aktivitäten überhaupt nichts im Sinn hatte!
Sogar eher da Gegenteil bewirken wollte ?
OTC Markt Interessierter den Namen eines Mannes zulegt,
der mit solchen Aktivitäten überhaupt nichts im Sinn hatte!
Sogar eher da Gegenteil bewirken wollte ?
Junge, denke das ist ein Börsenboard, in dem es um deren Inhalte geht, und nicht um irgendwelche Usernamen. Übrigens, wenn ich ernsthaft über philosophische oder soziologische, gar revolutionäre Themen sprechen wollte, dann sicherlich nicht hier. Hast du was zu Thermogenesis zu sagen, oder nicht? Schönen Tag noch, der Herr Dutschke empfiehlt sich.
Neuigkeiten, stelle sie später rein.
chart sieht ja gut aus ....
Hier die News:
THERMOGENESIS CORP. Signs Strategic European Distribution Agreement For World`s First
Autologous or Single Donor Fibrin Sealant System Revolutionary Fibrin Sealant Addresses Mad
Cow Concerns; Dideco S.p.A. to Sell CryoSeal(R) Fibrin Sealant in Europe
RANCHO CORDOVA, Calif., Feb 28, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced that it has signed a
distribution agreement with Dideco S.p.A., a Snia Group company located in
Mirandola, Italy to begin immediate commercialization of its CryoSeal Fibrin
Sealant (FS) System in Europe, Eastern Europe, portions of Scandinavia and the
Middle East, and Africa. The new system radically reduces Mad Cow concerns by
providing a fibrin sealant sourced from either the patient`s own blood or from a
single donor without any bovine additive. The company believes the annualized
worldwide market for fibrin sealant is approximately $500 million, of which $100
million is consumed by Europe alone.
"This is another important step for THERMOGENESIS as we continue our move from a
late stage Research and Development company to a revenue generating company,"
said Phil Coelho, Chief Executive Officer and Chairman of THERMOGENESIS CORP.
"Dideco is a leading European supplier of surgical blood management devices,
disposables, and services whose very large and established customer base will be
targets for the CryoSeal FS systems." Dr. Godsey, COO of THERMOGENESIS noted,
"The company believes CryoSeal Fibrin Sealant will be welcomed by patients and
surgeons in Europe because conventional fibrin sealants are sourced from `pools`
of thousands of purchased units of plasma plus a bovine additive." THERMOGENESIS
initiated a Phase III clinical trial of the CryoSeal FS system this quarter in
the U.S.
According to Dr. Mario Garzella, President and CEO of Dideco S.p.A., "The
ability to provide a `second generation` autologous and single donor fibrin
sealant into the European marketplace, where announcements of the spread of mad
cow disease, vCJD, and other infectious pathogens throughout Europe have caused
great concern, will provide Dideco with a major product differentiation point
and thus an advantage when selling into our large customer base." As part of its
contract evaluation process, Dideco conducted human clinical studies on the
CryoSeal FS system over a 6-month period.
The European fibrin sealant market is a mature market comprised primarily of two
large competitors, Baxter`s Tissucol and Aventis` Beriplast, with Baxter
International possessing the larger market share. Both competitors utilize
traditional fractionation processing to manufacture a first generation fibrin
sealant sourced from "pooled" plasma purchased from thousands of individuals, to
which bovine aprotinin has been added. Dideco will promote THERMOGENESIS`
CryoSeal Fibrin Sealant for use in both the autologous (using the patient`s own
plasma) and the allogeneic (using single donor plasma) settings, emphasizing the
ease of use of the product, the increased safety due to the lack of bovine
substances (or any other non-human proteins), and the benefits of having
additional wound healing proteins present at the wound site.
About THERMOGENESIS CORP.
After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce biotherapeutic products
from single units of blood. Cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of hematopoietic stem cells for bone marrow
rescue transplants while its CryoSeal System is used to prepare hemostatic and
adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS
CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.
About Dideco S.p.A.
Dideco is a world leader in the design and production of oxygenators and
extracorporeal blood circulation systems, which provide life support during open
heart surgery, taking over the functions normally performed by the patient`s
heart and lungs. Dideco manufactures a complete line of high performance
products for the surgical blood processing for adults and children. In 1993,
Dideco became the first company in the world to introduce a neonatal oxygenator.
The company also produces equipment and sterile disposable processing sets for
the therapeutic treatment of blood, which are used for self-transfusion and
apheresis applications.
Regulatory Status
In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. In
May 2001, the CryoSeal FS System received a license to market in Canada.
The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.
THERMOGENESIS CORP. Signs Strategic European Distribution Agreement For World`s First
Autologous or Single Donor Fibrin Sealant System Revolutionary Fibrin Sealant Addresses Mad
Cow Concerns; Dideco S.p.A. to Sell CryoSeal(R) Fibrin Sealant in Europe
RANCHO CORDOVA, Calif., Feb 28, 2002 /PRNewswire-FirstCall via COMTEX/ --
THERMOGENESIS CORP. (Nasdaq: KOOL) today announced that it has signed a
distribution agreement with Dideco S.p.A., a Snia Group company located in
Mirandola, Italy to begin immediate commercialization of its CryoSeal Fibrin
Sealant (FS) System in Europe, Eastern Europe, portions of Scandinavia and the
Middle East, and Africa. The new system radically reduces Mad Cow concerns by
providing a fibrin sealant sourced from either the patient`s own blood or from a
single donor without any bovine additive. The company believes the annualized
worldwide market for fibrin sealant is approximately $500 million, of which $100
million is consumed by Europe alone.
"This is another important step for THERMOGENESIS as we continue our move from a
late stage Research and Development company to a revenue generating company,"
said Phil Coelho, Chief Executive Officer and Chairman of THERMOGENESIS CORP.
"Dideco is a leading European supplier of surgical blood management devices,
disposables, and services whose very large and established customer base will be
targets for the CryoSeal FS systems." Dr. Godsey, COO of THERMOGENESIS noted,
"The company believes CryoSeal Fibrin Sealant will be welcomed by patients and
surgeons in Europe because conventional fibrin sealants are sourced from `pools`
of thousands of purchased units of plasma plus a bovine additive." THERMOGENESIS
initiated a Phase III clinical trial of the CryoSeal FS system this quarter in
the U.S.
According to Dr. Mario Garzella, President and CEO of Dideco S.p.A., "The
ability to provide a `second generation` autologous and single donor fibrin
sealant into the European marketplace, where announcements of the spread of mad
cow disease, vCJD, and other infectious pathogens throughout Europe have caused
great concern, will provide Dideco with a major product differentiation point
and thus an advantage when selling into our large customer base." As part of its
contract evaluation process, Dideco conducted human clinical studies on the
CryoSeal FS system over a 6-month period.
The European fibrin sealant market is a mature market comprised primarily of two
large competitors, Baxter`s Tissucol and Aventis` Beriplast, with Baxter
International possessing the larger market share. Both competitors utilize
traditional fractionation processing to manufacture a first generation fibrin
sealant sourced from "pooled" plasma purchased from thousands of individuals, to
which bovine aprotinin has been added. Dideco will promote THERMOGENESIS`
CryoSeal Fibrin Sealant for use in both the autologous (using the patient`s own
plasma) and the allogeneic (using single donor plasma) settings, emphasizing the
ease of use of the product, the increased safety due to the lack of bovine
substances (or any other non-human proteins), and the benefits of having
additional wound healing proteins present at the wound site.
About THERMOGENESIS CORP.
After extensive research, THERMOGENESIS CORP.`s newly introduced technology
platforms lead the world in their ability to produce biotherapeutic products
from single units of blood. Cord blood banks are utilizing the Company`s
BioArchive(R) System as a critical enabling technology for the harvesting,
processing and cryogenic archiving of hematopoietic stem cells for bone marrow
rescue transplants while its CryoSeal System is used to prepare hemostatic and
adhesive surgical sealants from patient blood in about an hour. THERMOGENESIS
CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma
Freezers and Thawers to hospitals and blood banks since 1992.
About Dideco S.p.A.
Dideco is a world leader in the design and production of oxygenators and
extracorporeal blood circulation systems, which provide life support during open
heart surgery, taking over the functions normally performed by the patient`s
heart and lungs. Dideco manufactures a complete line of high performance
products for the surgical blood processing for adults and children. In 1993,
Dideco became the first company in the world to introduce a neonatal oxygenator.
The company also produces equipment and sterile disposable processing sets for
the therapeutic treatment of blood, which are used for self-transfusion and
apheresis applications.
Regulatory Status
In March of 2001, the CryoSeal FS System received CE Mark approval from the
European Union Competent Authorities to initiate commercialization of the
CryoSeal FS System in Europe. The CryoSeal System is patent-protected, and will
require a pre-market approval by the U.S. FDA before marketing in the U.S. In
May 2001, the CryoSeal FS System received a license to market in Canada.
The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company`s control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company`s filings with the Securities and Exchange
Commission.
Hallo lucardes, verstehst du viel von Charttechnik? Wenn ja, wäre es sehr nett, wenn du hier mal den Chart analysieren könntest.
Tue mich etwas schwer mit der Technik, hoffe nur, dass wir heute Über 3$ schliessen, wäre dann das 52-Wochen-Hoch. Grüsse Rudi
P.S. bist natürlich auch ohne Analyse des Charts gern "gesehen"
Tue mich etwas schwer mit der Technik, hoffe nur, dass wir heute Über 3$ schliessen, wäre dann das 52-Wochen-Hoch. Grüsse Rudi
P.S. bist natürlich auch ohne Analyse des Charts gern "gesehen"
charttechnisch würde ich, ohne dass ich absoluter experte bin, sagen, dass THERMOGENESIS in intaktem aufwärtstrend verläuft und kurz davor steht, marke aus 09/2000 von von € 3,65 in angriff zu nehmen... aktie ist m.e. aber zurzeit etwas überkaft, sodass es bis zudiesem punkt noch kleinere rücksetzer geben kann. es sei denn es kommt nicht noch eine power-ad hoc...
l.
l.
Danke lucarde für diese schnelle Reaktion. Stelle hier gleich mal einen Chart rein, damit auch zu sehen ist, wovon wir reden.
muß jetzt los.
bis bald, morgen
ciao l.
bis bald, morgen
ciao l.
Hallo, hoffe das es klappt, kann den Chart leider nicht hier rein kopieren, suche gleich mal nach einer Alternative. Dies ist übrigens der 5-Jahres-Chart.Chart Options
http://www.tscn.com/frti/GR-R-KOOL-15440708-0-1-0-1300-570-4…
http://www.tscn.com/frti/GR-R-KOOL-15440708-0-1-0-1300-570-4…
Kann mal bitte jmd. sagen, ob der Chart durch anklicken des Links zu sehen ist? Danke
also bin kein profi, aber die Bollinger-BenderLinie
lässt charttechnisch ( ohne weitere Fundamentale Neuigkeiten)noch Platz bis 3,60$
oder intertretiere ich dies falsch, gebe keine Garantie*g*
lässt charttechnisch ( ohne weitere Fundamentale Neuigkeiten)noch Platz bis 3,60$
oder intertretiere ich dies falsch, gebe keine Garantie*g*
keine Ahnung, aber deinem Posting zu entnehmen funktioniert der Link.
wie gefällt euch eigentlich der Marketmaker in Berlin? Taxt im Gegensatz zu FSE sehr viel und reagiert auf den US-Kurs.
kool zieht meistens erst gegen Ende des Tages im Amiland an
Übrigens fritzchenl, schau mal auf Platz 22 der meistdiskutierten Aktien. Da sind wir.
So, mach jetzt erstmal Schluss, melde mich nach US-Börsenschluss nochmal. Auf das der Kurs weiter steigt.
sorry rudi war ne falsche Meldung von mir vorher
der Kurs streicht die obere Bollingerbender linie
also hier charttechnisch gesehen ein Verkauf
wohlgemerkt nur charttechnisch
Im Klartext heist das das zu 95% charttechnisch gesehen es wieder tiefere Kurse gibt
der Kurs streicht die obere Bollingerbender linie
also hier charttechnisch gesehen ein Verkauf
wohlgemerkt nur charttechnisch
Im Klartext heist das das zu 95% charttechnisch gesehen es wieder tiefere Kurse gibt
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 210 | ||
| 92 | ||
| 91 | ||
| 63 | ||
| 49 | ||
| 48 | ||
| 40 | ||
| 36 | ||
| 33 | ||
| 30 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 23 | ||
| 23 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 |
